These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

593 related items for PubMed ID: 30811141

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Efficacy and Tolerability of a Novel Tretinoin 0.05% Lotion for the Once-Daily Treatment of Moderate or Severe Acne Vulgaris in Adult Females.
    Harper JC, Baldwin H, Stein Gold L, Guenin E.
    J Drugs Dermatol; 2019 Nov 01; 18(11):1147-1154. PubMed ID: 31741360
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Tretinoin 0.05% Lotion for the Once-Daily Treatment of Moderate-to-Severe Acne Vulgaris: Impact of Gender and Race on Efficacy and Safety.
    Lain E, Day D, Harper J, Guenin E.
    J Drugs Dermatol; 2019 Nov 01; 18(11):1128-1138. PubMed ID: 31741356
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Novel Polymeric Lotion Formulation of Once-Daily Tazarotene (0.045%) for Moderate-to-Severe Acne: Pooled Phase 3 Analysis.
    Tanghetti EA, Werschler WP, Lain E, Guenin E, Harris S, Loncaric A, Pillai R.
    J Drugs Dermatol; 2020 Mar 01; 19(3):272-279. PubMed ID: 32549090
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. New Polymeric Once-Daily Tazarotene 0.045% Lotion Formulation for Moderate-to-Severe Acne: Pooled Phase 3 Pediatric Analysis.
    Eichenfield LF, Tanghetti EA, Guenin E, Martin G, Pillai R.
    J Drugs Dermatol; 2020 Jun 01; 19(6):602-610. PubMed ID: 32574011
    [Abstract] [Full Text] [Related]

  • 13. Novel Tretinoin 0.05% Lotion for the Once-daily Treatment of Moderate-to-severe Acne Vulgaris in a Preadolescent and Adolescent Population.
    St Surin-Lord S, Schlesinger TE, Guenin E.
    J Clin Aesthet Dermatol; 2019 Sep 01; 12(9):E57-E61. PubMed ID: 31641421
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. The Effects of Once-Daily Tretinoin 0.05% Lotion on Quality of Life in Patients with Moderate-to-Severe Acne Vulgaris.
    Tyring SK, Kircik L, Pariser DM, Woolery-Lloyd HC, Harper JC, Bhatt V, Pillai R, Guenin E.
    Am J Clin Dermatol; 2020 Dec 01; 21(6):891-899. PubMed ID: 32886337
    [Abstract] [Full Text] [Related]

  • 16. A Phase 2, Multicenter, Double-Blind, Randomized, Vehicle-Controlled Clinical Study to Compare the Safety and Efficacy of a Novel Tazarotene 0.045% Lotion and Tazarotene 0.1% Cream in the Treatment of Moderate-to-Severe Acne Vulgaris.
    Tanghetti EA, Kircik LH, Green LJ, Guenin E, Harris S, Martin G, Pillai R.
    J Drugs Dermatol; 2019 Jun 01; 18(6):542. PubMed ID: 31251546
    [Abstract] [Full Text] [Related]

  • 17. Novel tretinoin 0.05% lotion for the once-daily treatment of moderate-to-severe acne vulgaris: assessment of safety and tolerability in subgroups.
    Harper JC, Roberts WE, Zeichner JA, Guenin E, Bhatt V, Pillai R.
    J Dermatolog Treat; 2020 Mar 01; 31(2):160-167. PubMed ID: 30935257
    [Abstract] [Full Text] [Related]

  • 18. Tazarotene 0.045% Lotion for Moderate-to-Severe Acne Patients: Pooled Phase 3 Analysis by Age and Sex.
    Green LJ, Del Rosso JQ, Tanghetti EA, Guenin E.
    J Drugs Dermatol; 2021 Jun 01; 20(6):608-615. PubMed ID: 34076400
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 30.